facebook_pixel

Equity Strategies

Equity Strategy 24 October 2019
BLUE PHOENIX FINANCIALS PREMIUM CONTENT Not a member? Join Now!
AstraZeneca: Buy. Profit From A Cancer Play

AstraZeneca: Buy. Profit From A Cancer Play

  AstraZeneca’s stock climbed on Thursday as the British drugmaker raised sales guidance after soaring demand for its new cancer drugs   The pharmaceutical giant’s third quarter results beat profit and sales expectations, sending the stock 3.8% higher   The Anglo-Swedish drugmaker returned to sales growth last year for the first time since 2014 as […]

FIND OUT MORE

Equity Strategy 18 October 2019
BLUE PHOENIX FINANCIALS PREMIUM CONTENT Not a member? Join Now!
Microsoft: Keep On Buying Before Earnings

Microsoft: Keep On Buying Before Earnings

  RBC boosts its Microsoft target from $153 to $160, calling the company “one of the most likely outperformers over a multi-year period.”   Analyst Alex Zukin also names MSFT “King of Cloud” with outperformance dependent on helping enterprises “seamlessly” move to the cloud   Upcoming catalyst: Microsoft will report earnings on October 23 and RBC expects the typical […]

FIND OUT MORE

Equity Strategy 16 October 2019
BLUE PHOENIX FINANCIALS PREMIUM CONTENT Not a member? Join Now!
Johnson & Johnson: Buy. Its All Systems Go

Johnson & Johnson: Buy. Its All Systems Go

  Johnson & Johnson shares extended gains Wednesday amid reports it could be close to agreeing a multi-billion dollar settlement with state attorneys general over its role in the nation’s opioid crisis   Bloomberg reported late Tuesday that Johnson & Johnson has offered to pay around $4 billion to wipe out claims against it linked to […]

FIND OUT MORE

Equity Strategy 16 October 2019
BLUE PHOENIX FINANCIALS PREMIUM CONTENT Not a member? Join Now!
Abbott Labs: Buy. The Party Is Starting

Abbott Labs: Buy. The Party Is Starting

  On Wednesday before the opening bell, Abbott Laboratories (ABT) reported in line earnings, with a marginal miss on the top line with its third-quarter 2019 results   Revenues of $8.076 billion (+5.5% YoY) came in just short versus the $8.105 billion consensus, while adjusted earnings per share of $0.84 (+12.0% YoY) was right on par with expectations […]

FIND OUT MORE

Equity Strategy 16 October 2019
BLUE PHOENIX FINANCIALS PREMIUM CONTENT Not a member? Join Now!
Chipotle Mexican Grill: Buy. Get Ready For The Next Phase

Chipotle Mexican Grill: Buy. Get Ready For The Next Phase

  Chipotle Mexican Grill stock has had a great year, and KeyBanc Capital Markets expects that strength to continue into the burrito chain’s upcoming third-quarter earnings report, due out next week   The back story. Chipotle stock (ticker: CMG) has soared 90% in 2019—a period that’s seen the S&P 500 rise less than 20%—defeating even the staunchest […]

FIND OUT MORE